Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note published on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

Shares of Cumberland Pharmaceuticals stock opened at $1.55 on Friday. Cumberland Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $2.36. The stock has a market capitalization of $21.99 million, a price-to-earnings ratio of -2.63 and a beta of 0.17. The company has a fifty day moving average of $1.65 and a 200-day moving average of $1.81. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.21 and a current ratio of 1.37.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 21.67% and a positive return on equity of 0.21%. The business had revenue of $8.50 million during the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp purchased a new stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned 0.52% of Cumberland Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.